San Francisco—An experimental cancer therapy is expected to dramatically change the way clinicians treat patients with chronic myelogenous leukemia (CML), according to researchers presenting the latest findings from phase 2 trials involving more than 1000 patients with the disease.
The new findings, as well as results from other studies reported here at the annual meeting of the American Society of Hematology (ASH), reveal that an ever more sophisticated understanding of genetic and cellular mechanisms is beginning to bear fruit in the form of new therapeutic approaches for a wide range of disorders, from cancer to hemophilia to heart disease.
Stephenson J. New Therapies Show Promise for Patients With Leukemia, Hemophilia, and Heart Disease. JAMA. 2001;285(2):153-155. doi:10.1001/jama.285.2.153